Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Total Liabilities (2020 - 2025)

Bolt Biotherapeutics (BOLT) has disclosed Total Liabilities for 6 consecutive years, with $30.2 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 28.73% to $30.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $30.2 million through Dec 2025, down 28.73% year-over-year, with the annual reading at $30.2 million for FY2025, 28.73% down from the prior year.
  • Total Liabilities hit $30.2 million in Q4 2025 for Bolt Biotherapeutics, down from $33.0 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $58.6 million in Q3 2021 to a low of $21.4 million in Q1 2021.
  • Historically, Total Liabilities has averaged $44.8 million across 5 years, with a median of $47.1 million in 2023.
  • Biggest five-year swings in Total Liabilities: tumbled 60.56% in 2021 and later soared 154.33% in 2022.
  • Year by year, Total Liabilities stood at $57.6 million in 2021, then fell by 2.25% to $56.3 million in 2022, then decreased by 16.44% to $47.0 million in 2023, then dropped by 9.8% to $42.4 million in 2024, then fell by 28.73% to $30.2 million in 2025.
  • Business Quant data shows Total Liabilities for BOLT at $30.2 million in Q4 2025, $33.0 million in Q3 2025, and $36.7 million in Q2 2025.